Know Labs, Inc. (ASE:KNW) Q1 2023 Earnings Call Transcript

The short answer is the focus is on blood glucose. We have, in the past, announced our capacity to identify blood alcohol levels, blood oxygen levels, and identify the presence of tylenol and aspirin after they’ve been ingested, which is really a proxy for the therapeutics. At this time, our focus is on glucose. We do believe over time, as we’ve indicated, that there will be a number of other analytes that we’re going to be able to identify. Those all relate to human health, and we think there are really going to be significant opportunities to do things with our technology over the years to come. But for now, the focus is on glucose as it must be. That concludes our Q&A. I want to thank everyone for joining us this afternoon. As I’d love to look forward in 2023 and we’re excited to report on our progress, I know I speak with many of you, so to speak, Conley.

We’re happy to entertain those calls, so don’t be a stranger. We appreciate your support and we want to acknowledge the incredible effort of our team, of our wonderful talented employees. With that, I want to thank you. Have a great day, and I have to end by saying because it is the 14th of February, Happy Valentine’s Day to everyone out there, and thank you for dialing in, for participating. We appreciate it very, very much.

Jordyn Hujar: Thanks, Ron. The conference call replay will be available on our website in the coming days. Thank you, everyone, for your participation.

Q – :

Operator: Thank you. That does conclude today’s teleconference and webcast. You may now disconnect.